Literature DB >> 6421562

[Prolonged coma caused by diazepam sedation in ventilated patients. Diagnostic and therapeutic use of the benzodiazepine antagonist Ro 15-1788].

H J Rapold, F Follath, G Scollo-Lavizzari, O Kehl, R Ritz.   

Abstract

Repeated administration of diazepam in two ventilated patients had caused drug cumulation and coma over several days. In both cases central nervous depression could be demonstrated by the benzodiazepin antagonist Ro 15-1788 which induced reversal of coma. Estimation of plasma concentrations in a 70-year-old female patient 150 hours after the last administration showed a diazepam concentration of 437 ng/ml and a desmethyl-diazepam concentration of 483 ng/ml. The calculated elimination half-life of these substances were 109 and 403 hours. In the second case benzodiazepin could be demonstrated in urine for 10 days after withdrawal of medication. These observations suggest that diazepam is not a suitable drug for prolonged sedation in artificially ventilated patients. The benzodiazepin antagonist Ro 15-1788 represents a valuable diagnostic aid in ascertained or suspect cases of benzodiazepin intoxications. It can also be used therapeutically for reversal of central nervous depression.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6421562     DOI: 10.1055/s-2008-1069192

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  4 in total

Review 1.  Benzodiazepine sedation in adult ICU patients.

Authors:  R Ritz
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

2.  Use of flumazenil in intoxicated patients with coma. A double-blind placebo-controlled study in ICU.

Authors:  R Ritz; M Zuber; S Elsasser; G Scollo-Lavizzari
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 3.  Pharmacokinetics and clinical use of flumazenil (Ro 15-1788).

Authors:  U Klotz; J Kanto
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

4.  Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788.

Authors:  U Klotz; T Duka; R Dorow; A Doenicke
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.